JP2018515557A - うつ病を治療するための方法及びキット - Google Patents

うつ病を治療するための方法及びキット Download PDF

Info

Publication number
JP2018515557A
JP2018515557A JP2017560314A JP2017560314A JP2018515557A JP 2018515557 A JP2018515557 A JP 2018515557A JP 2017560314 A JP2017560314 A JP 2017560314A JP 2017560314 A JP2017560314 A JP 2017560314A JP 2018515557 A JP2018515557 A JP 2018515557A
Authority
JP
Japan
Prior art keywords
esketamine
during
patient
administered
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017560314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515557A5 (enExample
Inventor
シン，ジャスカラン
カエルス，イヴォ
ダリー，エラ
シー． ドレヴェツ，ワイン
シー． ドレヴェツ，ワイン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2018515557A publication Critical patent/JP2018515557A/ja
Publication of JP2018515557A5 publication Critical patent/JP2018515557A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017560314A 2015-05-20 2016-05-20 うつ病を治療するための方法及びキット Pending JP2018515557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20
US62/164,026 2015-05-20
PCT/US2016/033404 WO2016187491A1 (en) 2015-05-20 2016-05-20 Methods and kits for treating depression

Publications (2)

Publication Number Publication Date
JP2018515557A true JP2018515557A (ja) 2018-06-14
JP2018515557A5 JP2018515557A5 (enExample) 2019-06-13

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560314A Pending JP2018515557A (ja) 2015-05-20 2016-05-20 うつ病を治療するための方法及びキット

Country Status (20)

Country Link
US (1) US20160338977A1 (enExample)
EP (1) EP3297618A4 (enExample)
JP (1) JP2018515557A (enExample)
KR (1) KR20180008634A (enExample)
CN (1) CN107735081A (enExample)
AU (3) AU2016263598A1 (enExample)
CA (1) CA2986477A1 (enExample)
CL (1) CL2017002904A1 (enExample)
CO (1) CO2017011564A2 (enExample)
DO (1) DOP2017000268A (enExample)
EA (1) EA201792545A1 (enExample)
EC (1) ECSP17077930A (enExample)
GT (1) GT201700246A (enExample)
HK (1) HK1252937A1 (enExample)
IL (1) IL255463A (enExample)
MA (1) MA42135A (enExample)
MX (1) MX2017014797A (enExample)
PE (1) PE20180260A1 (enExample)
PH (1) PH12017502103A1 (enExample)
WO (1) WO2016187491A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
JP2022502429A (ja) * 2018-09-28 2022-01-11 セロン ファーマ エス.アー.Celon Pharma S.A. 肺投与によるうつ病の処置方法における使用のためのケタミン組成物
JP2022504036A (ja) * 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害を治療するためのエスケタミンの投与計画
JP2022524008A (ja) * 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
US12076300B2 (en) 2019-12-30 2024-09-03 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
SG11202005896WA (en) * 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) * 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP4021432A4 (en) * 2019-08-28 2023-08-16 Janssen Pharmaceuticals, Inc. ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021242504A1 (en) * 2020-05-28 2021-12-02 Janssen Pharmaceuticals, Inc. Methods for treating depression
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US20140221473A1 (en) * 2011-06-30 2014-08-07 Jahanshah Amin Compositions, Methods of Use, and Methods of Treatment
WO2014169272A1 (en) * 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3193853A1 (en) * 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20140221473A1 (en) * 2011-06-30 2014-08-07 Jahanshah Amin Compositions, Methods of Use, and Methods of Treatment
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2014169272A1 (en) * 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"うつ病に対する薬の使い時，止め時−薬物療法の現状 Starting and stopping pharmacotherapy of depr", 医学のあゆみ 第２１９巻 第１３号, vol. 219, no. 13, JPN6020010730, 2006, pages 949 - 953, ISSN: 0004402024 *
岡山医学会雑誌, vol. 119, JPN6020010733, 2008, pages 315 - 317, ISSN: 0004402025 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP7903800B2 (ja) 2018-06-27 2026-08-12 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
JP2022502429A (ja) * 2018-09-28 2022-01-11 セロン ファーマ エス.アー.Celon Pharma S.A. 肺投与によるうつ病の処置方法における使用のためのケタミン組成物
JP7444864B2 (ja) 2018-09-28 2024-03-06 セロン ファーマ エス．アー． 肺投与によるうつ病の処置方法における使用のためのケタミン組成物
US12280022B2 (en) 2018-10-05 2025-04-22 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022504036A (ja) * 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害を治療するためのエスケタミンの投与計画
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12514831B2 (en) 2018-10-05 2026-01-06 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12336970B2 (en) 2018-10-05 2025-06-24 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022524008A (ja) * 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
JP2025003983A (ja) * 2019-03-05 2025-01-14 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
US12268658B2 (en) 2019-12-30 2025-04-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
US12076300B2 (en) 2019-12-30 2024-09-03 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Also Published As

Publication number Publication date
DOP2017000268A (es) 2018-04-15
WO2016187491A1 (en) 2016-11-24
GT201700246A (es) 2019-07-29
PE20180260A1 (es) 2018-02-05
EA201792545A1 (ru) 2018-05-31
HK1252937A1 (zh) 2019-06-06
AU2016263598A1 (en) 2017-11-23
CA2986477A1 (en) 2016-11-24
PH12017502103A1 (en) 2018-05-07
EP3297618A1 (en) 2018-03-28
CL2017002904A1 (es) 2018-04-20
MX2017014797A (es) 2018-02-15
ECSP17077930A (es) 2018-02-28
US20160338977A1 (en) 2016-11-24
MA42135A (fr) 2018-03-28
CN107735081A (zh) 2018-02-23
EP3297618A4 (en) 2019-01-23
KR20180008634A (ko) 2018-01-24
IL255463A (en) 2018-01-31
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
AU2021215155A1 (en) 2021-09-02
CO2017011564A2 (es) 2018-04-19

Similar Documents

Publication Publication Date Title
AU2023237026A1 (en) Methods and kits for treating depression
Aan Het Rot et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression
US20230089113A1 (en) Methods For The Treatment Of Depression
Suppes et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder
CA3086478A1 (en) Esketamine for the treatment of depression
US20130236573A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US20240325296A1 (en) Esketamine for the treatment of depression
JP7273037B2 (ja) ３－メチルメトカチノンの使用
CN103298462A (zh) 降低暴食或强迫进食的方法
Fineberg et al. Pharmacotherapy for obsessive—compulsive disorder
Bourke Fibromyalgia and chronic fatigue syndrome: management issues
Haghparast et al. Sedatives and hypnotics
Fujioka Sustained-release naltrexone/bupropion-a novel pharmacologic approach to obesity and food craving
JP2019514978A (ja) イブジラストを使用したアルコール依存症並びにうつ病及び／又は不快な気分の治療
JP7840873B2 (ja) うつ病の治療方法
Sanacora Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants.
RU2788450C2 (ru) Способы проведения терапии потери веса у пациентов с доминирующей депрессией
Ketter et al. Overview of pharmacotherapy for Bipolar Disorder
AU2013201492A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
Trinza DA US FDA Approved for
Rizek et al. Management of Advanced Parkinson’s Disease
Frieden White House announces health IT grants
Bradford et al. Therapy: Recent Progress in Clinical Applications and Research in Fibromyalgia--Part 3
Naidoo et al. P. 4. c. 003 Mother's little helper: prescribing practice of anxiolytics and hypnotics in a community mental health team

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210706